anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Increasing numbers of research studies have offered evidence regarding awareness of verified events during near-death experiences (NDEs) occurring during cardiac arrest and severely impaired brain function. The prevalence of patients reporting core NDEs under these conditions is reported as 10-12 %. One question that is often asked is why this percentage is low. Though it may be hypothesized that NDEs are limited to this low percentage of patients, it is also possible that more patients experience an NDE, but that memory is impaired sufficiently such that the NDE is not recalled. In this article I present a detailed and extensively verified case study of a woman, Stephanie Arnold, who experienced an NDE during the birth of her second child when she was 41 years old. The data provide evidence that supports the hypotheses 1) that during cardiac arrest an NDE may occur, but not be remembered until hypnotic regression therapy reveals extensive details of the events that could not have been perceived with the five senses, both in the operating room and elsewhere during resuscitation. 2) that there may also be pre-cognition of the events leading to the cardiac arrest, reported in clear detail, and 3) that NDEs lead to a fundamental transformation in an individual's understanding of the nature of consciousness, their quest for meaning and purpose, their concern for others, and their appreciation of life.
Computer-implemented methods, computer-readable storage media, and computer systems for associating received medical imaging data with stored medical imaging data. Medical imaging data associated with a patient is received from a client device. The medical imaging data includes an image object, one or more data objects related to the image object, and metadata associated with the patient encoded in Digital Imaging and Communication in Medicine (DICOM) format. The metadata includes personal information about the patient, and time and location at which the DICOM image file was captured. The received metadata is compared with existing metadata associated with multiple existing patients to identify a subset of the existing patients who may be a potential match to the patient. Selection of an existing patient from among the subset is requested. When received, the medical imaging data is associated with the existing patient.
Postoperative delirium remains a common postoperative problem in critically ill patients with a prevalence of up to 20% and even up to 50% in the elderly population. But postoperative delirium has a negative impact on mortality as several studies were able to show in the past. Therefore, aiming for a reduction of postoperative delirium has an important impact on patients' outcome. One helpful tool for avoiding postoperative delirium is maintaining a circadian pattern. Enteral feeding may play an important role here. Healthy humans have a circadian feeding pattern with nighttime fasting. There is increasing evidence that a circadian rhythm of feeding (cyclic feeding) could be beneficial for critical ill patients. Cyclic feeding and fasting are assumed to have positive effects on the gut microbiome resulting in optimization of host responses to gastrointestinal pathogens. Another positive effect of cyclic feeding potentially results from activation of a "fasting response", inducing repair pathways such as ketogenesis, mitochondrial biogenesis, anti-inflammatory pathways, antioxidant defenses and autophagy processes. The activation of these repair pathways could diminish cellular stress and promote cellular recovery in critical ill patients. This could have a positive effect on postoperative delirium. A randomized controlled trial by van Dyck et al. could show that fasting-mimicking intervals of 12 hours are sufficient to generate a metabolic fasting response without risking a caloric deficit. This fasting response can be enhanced by additional supplementation of exogenous ketones. The study objective is that equicaloric cyclic enteral feeding (for 12 hours) during daytime with ketogenic fasting (for 12 hours) at nighttime (aiming for a ß-hydroxybutyrate blood concentrations ≥ 0.5mM by exogenous ketone supplementation) compared to continuous (for 24 hours) standard enteral nutrition as per patients' nutritional requirements decreases the incidence of postoperative delirium of critically ill patients.
An extracellular vesicle (EV) is a nano-sized vesicle consisting of a proteolipid bilayer with various molecular characteristics of cells. EVs are a medium for intercellular communication and are receiving great attention as a new therapeutic agent in the field of nanomedicine. Accordingly, many studies are exploring the role of cell-derived EVs isolated from cultured hepatocytes or stem cells as inducers of liver proliferation and regeneration in various pathological settings. However, there has been no study of exploring the role of EV directly isolated from liver tissues. In this study, EVs were isolated from normal in vivo liver tissue and carbon tetrachloride (CCl_4)-induced injured in vivo liver tissue to understand the pathophysiological role of liver EVs in vivo and investigate their therapeutic potential. In vivo EVs purified from liver tissues exhibit typical characteristics of EVs, including spherical morphology, nano-size, and abundant tetraspanins. Interestingly, the administrations of normal liver EV and injured liver EV significantly accelerated the recovery of liver tissue from CCl_4-induced liver necrosis. The reparative action was achieved through the induction of hepatocyte growth factors at the site of injury. These results suggest that not only normal liver EVs but also injured liver EVs play an important pathophysiological role in maintaining homeostasis after tissue injury. Therefore, the present invention provides new insights into in vivo EV-based therapeutics that could be developed for the prevention and treatment of liver diseases.
After the root canal preparation was completed, the working length was controlled with the master cone and periapical radiography. Root canal sealer was applied to the root canal walls using a master cone. Root canal obturation was completed with heated gutta-percha according to the manufacturer's instructions. The heated gutta-percha was slowly inserted into the canal up to the working length. After cutting the handle of the obturators at the level of the canal orifice with a hot excavator, it was condensed into the canal using a gutta-percha plugger. The coronal gutta-percha was removed 1 mm below the canal orifice using a hot excavator.
Nimodipine, an L-type cerebroselective calcium channel antagonist, is the only drug approved by the US Food and Drug Administration for the neuroprotection of patients with aneurysmal subarachnoid hemorrhage (aSAH). Four randomized, placebo-controlled trials of nimodipine demonstrated clinical improvement over placebo; however, these occurred before precision medicine with pharmacogenomics was readily available. The standard enteral dose of nimodipine recommended after aSAH is 60 mg every 4 h. However, up to 78% of patients with aSAH develop systemic arterial hypotension after taking the drug at the recommended dose, which could theoretically limit its neuroprotective role and worsen cerebral perfusion pressure and cerebral blood flow, particularly when concomitant vasospasm is present. We investigated the association between nimodipine dose changes and clinical outcomes in a consecutive series of 150 patients (mean age, 56 years; 70.7% women) with acute aSAH. We describe the pharmacogenomic relationship of nimodipine dose reduction with clinical outcomes. These results have major implications for future individualized dosing of nimodipine in the era of precision medicine.
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical preparation for oral administration having strong stegnotic effects.  <P>SOLUTION: The pharmaceutical preparation for the oral administration comprising (A) oxethazaine and (B) at least one kind selected from the group consisting of Mallotus japonicus and an extract therefrom is provided. The pharmaceutical preparation for the oral administration prepared by combining (A) the oxethazaine with (B) at least the one kind selected from the group consisting of the Mallotus japonicus and the extract therefrom is provided. In the pharmaceutical preparation for the oral administration, the amount of (B) at least the one kind selected from the group consisting of the Mallotus japonicus and the extract therefrom is 0.3-500 pts.wt. converted into the original crude drug and based on 1 pt.wt. of (A) the oxethazaine. The pharmaceutical preparation for the oral administration can be used for treatment and/or prophylaxis of diarrhea.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a pathologically active peptide having an inhibitory activity against cell adhesion composed of amino acids of specific residue number, having a specific amino acid sequence, an antagonistic action on a cell adhesion factor for furthering diseases such as cancer, inflammation, fiberization of organ, etc., and on a ligand molecule action against the cell adhesion factor. SOLUTION: This pathologically active peptide has cell adhesion inhibitory activity composed of amino acids of <=30 residues and amino acid sequences of formula I to formula V. A hydrophilic amino acid or a substance containing a hydrophilic group (e.g. ethylene glycol, etc.), can be added to the peptide. The peptide is obtained preferably by a chemical synthesis method for an oligopeptide, a biological method or a genetic engineering method. A solid-phase synthesis method is preferable as a chemical synthesis method. Preferably the obtained peptide is purified by a peptide purification method (e.g. column chromatography). In the case of administering the peptide as a therapeutic agent, the dose is 1-100,000 μm/kg weight/day.
All patients in Stage I (N=12) and Stage II (N=25) will receive FOLFOX-A on days 1 and 15 of each cycle (1 cycle = 28 days). Nab-paclitaxel will be given at a dose of 150 mg/m\^2 IV over 30 minutes, followed by oxaliplatin IV 85 mg/m\^2 and leucovorin IV 400 mg/m\^2 over 2 hours, and 5-FU as a continuous IV infusion over Day 1 and Day 2 (for a total dose of 2400mg/m\^2 over 46-48 hours.). Radiographic assessment will be performed at baseline and every other cycle (starting with Cycle 3) to evaluate response to treatment by RECIST Version 1.1 guidelines. Patients may continue to receive treatment until disease progression or unacceptable toxicity.
Patients randomized in "STANDARD FACE MASK" group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. No specific trademark is requested by the protocol.
A-dmDT390-bisFv(UCHT1) (Resimmune™), an anti-T cell immunotoxin is currently being studied as a treatment for cutaneous T cell lymphoma and other CD3+ malignant diseases (FDA IND Number: 100712, Scott and White Protocol 071163). During the course of this study, data accumulated that Resimmune could be acting as an immunomodulator. This was based on the observation that four out of six partial responses converted to complete responses at times ranging between 6 and 24 months following the completion of the 4-day treatment protocol and no other treatment took place.

The purpose of this trial is to test the hypothesis that Resimmune can act as an immunomodulator of late stage metastatic melanoma when combined with palliative radiation to induce the priming of activated T cells with tumor antigens. The primary objective of this study is to determine the safety of combining Resimmune with palliative radiation therapy in patients with stage IV melanoma. A secondary objective is to document the tumor response and duration of response at irradiated and unirradiated sites (the abscopal effect). An additional secondary objective is to determine if T cell activation occurs following administration of A-dmDT390-bisFv(UCHT1) and local radiation to a metastatic lesion of melanoma.
A 48-week, randomized, double-blind, placebo-controlled study enrolled 211 pediatric subjects 4 to 17 years of age, with moderate to severe plaque psoriasis (PsO) (as defined by a sPGA score ≥ 3 [moderate, marked, or severe], involving ≥ 10% of the body surface area, and a PASI score ≥ 12) who were candidates for phototherapy or systemic therapy, or were inadequately controlled on topical therapy. Subjects in all treatment groups had a median baseline PASI score of 16.4, and the percentage of subjects with baseline sPGA classifications was 65% for moderate, 31% for marked, and 3% for severe. Across all treatment groups, the percentage of subjects who previously received systemic or phototherapy for PsO was 57%. 

Subjects received Enbrel 0.8 mg/kg (up to a maximum of 50 mg per dose) or placebo once weekly for the first 12 weeks. After 12 weeks, subjects entered a 24-week open-label treatment period, in which all subjects received Enbrel at the same dose. This was followed by a 12-week withdrawal-retreatment period. 

Response to treatment was assessed after 12 weeks of therapy and was defined as the proportion of subjects who achieved a reduction in PASI score of at least 75% from baseline. The PASI is a composite score that takes into consideration both the fraction of body surface area affected and the nature and severity of psoriatic changes within the affected regions (induration, erythema and scaling).

Other evaluated outcomes included the proportion of subjects who achieved a score of "clear" or "almost clear" by the sPGA and the proportion of subjects with a reduction in PASI score of at least 90% from baseline. The sPGA is a 6-category scale ranging from "5 = severe" to "0 = none" indicating the physician's overall assessment of the PsO severity focusing on induration, erythema and scaling. Treatment success of "clear" or "almost clear" consisted of none or minimal elevation in plaque, up to faint red coloration in erythema and none or minimal fine scale over < 5% of the plaque.

Efficacy results are summarized in Table 15.

Maintenance of Response

To evaluate maintenance of response, subjects who achieved PASI 75 response at Week 36 were re-randomized to either Enbrel or placebo during a 12-week randomized withdrawal period. The maintenance of PASI 75 response was evaluated at Week 48. The proportion of subjects who maintained PASI 75 response at Week 48 was higher for subjects treated with Enbrel (65%) compared to those treated with placebo (49%).
Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
BACKGROUND: The prognostic and therapeutic implications of endothelial cells (ECs) heterogeneity in prostate cancer (PCa) are poorly understood.
METHODS: We investigated associations of EC heterogeneity with PCa recurrence and castration resistance in 8 bulk transcriptomic and 4 single-cell RNA-seq cohorts. A recurrence-associated EC (RAEC) signature was constructed by comparing 11 machine learning algorithms through nested cross-validation. Functional relevances of RAEC-specific genes were also tested.
RESULTS: A subset of ECs was significantly associated with recurrence in primary PCa and named RAECs. RAECs were characteristic of tip and immature cells and were enriched in migration, angiogenesis, and collagen-related pathways. We then developed an 18-gene RAEC signature (RAECsig) representative of RAECs. Higher RAECsig scores independently predicted tumor recurrence and performed better or comparably compared to clinicopathological factors and commercial gene signatures in multiple PCa cohorts. Of the 18 RAECsig genes, FSCN1 was upregulated in ECs from PCa with higher Gleason scores; and the silencing of FSCN1, TMEME255B, or GABRD in ECs either attenuated tube formation or inhibited PCa cell proliferation. Finally, higher RAECsig scores predicted castration resistance in both primary and castration-resistant PCa.
CONCLUSION: This study establishes an endothelial signature that links a subset of ECs to prostate cancer recurrence and castration resistance.
PURPOSE: Spinal tuberculosis, if not promptly treated, can lead to kyphotic deformity, causing persistent neurological abnormalities and discomfort. Spinal cord compression can occur due to ossification of the ligamentum flavum (OLF) at the apex of kyphosis. Traditional surgical interventions, including osteotomy and fixation, pose challenges and risks. We present a case of thoracic myelopathy in a patient with post-tuberculosis kyphosis, successfully treated with biportal endoscopic spinal surgery (BESS).
METHOD: A 73-year-old female with a history of untreated kyphosis presented with walking difficulties and lower limb pain. Imaging revealed a kyphotic deformity of 120° and OLF-induced cord compression at T8-9. UBE was performed under spinal anesthesia. Using the BESS technique, OLF was successfully removed with minimal damage to the stabilizing structures.
RESULTS: The patient exhibited neurological improvement after surgery, walking on the first day without gait instability. Follow-up at 1 year showed no kyphosis progression or recurrence of symptoms. BESS successfully resolved the cord compression lesion with minimal blood loss and damage.
CONCLUSION: In spinal tuberculosis-related OLF, conventional open surgery poses challenges. BESS emerges as an excellent alternative, providing effective decompression with reduced instrumentation needs, minimal blood loss, and preservation of surrounding structures. Careful patient selection and surgical planning are crucial for optimal outcomes in endoscopic procedures.
The physiotherapy experimental group received core stability based physiotherapy treatment. Before the beginning of the treatment sessions, the basic principles of core stability exercises were explained to the participants. The exercise programme included 7 exercises. The exercises in the crook lying position were core activation with breathing, single leg lift with knees bent, single leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight. After each session gentle stretching of the lower limbs and lumbar spine were performed. The sessions were administered twice a week during 30 minutes with groups of no more than 8 people.
In all clinical trials, the dose for ropinirole tablets USP was initiated at 0.25 mg once daily, 1 to 3 hours before bedtime. Patients were titrated based on clinical response and tolerability. 

The recommended adult starting dosage for RLS is 0.25 mg once daily, 1 to 3 hours before bedtime. After 2 days, the dosage can be increased to 0.5 mg once daily and to 1 mg once daily at the end of the first week of dosing, then as shown in Table 6 as needed to achieve efficacy. For RLS, the safety and effectiveness of doses greater than 4 mg once daily have not been established. 

In clinical trials of patients being treated for RLS with doses up to 4 mg once daily, ropinirole hydrochloride was discontinued without a taper.
The invention relates to a W/O vaccine oil adjuvant formulation and a preparation method thereof. The formulation is a W/O emulsion, which comprises an aqueous phase containing a solution of antigen and an oil phase containing white oil, an emulsifier, and a stabilizing agent. The W/O emulsion has the average particle size in a range of 0.1-8.22 [mu]m and the coefficient of dispersion less than 0.1. The preparation method comprises: transferring a pre-emulsion into a storage tank for quick membrane emulsification, and allowing the obtained product to pass through a microporous membrane under the pressure in a range of 0.1-2.5 MPa to obtain the W/O vaccine oil adjuvant formulation. The W/O vaccine oil adjuvant formulation is uniform and controllable in size. The improved uniformity of the emulsion benefits enhancement of stability of emulsion droplets. Compared with an emulsion prepared through a conventional process, the emulsion in the invention is slower in the Ostwald ripening, so that when the formulation is injected into a human body, the burst release of antigen is at a low speed, and antigen can be continuously released later, thereby inducing a quick, efficient and continuous immune response level.
PURPOSE:To provide the titled remedy for athlete's foot composed mainly of extracted liquid of hibiscus. CONSTITUTION:Extracted liquid of the root of hibiscus is deodorized with activated charcoal and mixed with salicyclic acid, glycerol and lactic acid to obtain a pasty composition, which is used as the base. A fatty acid, an aliphatic higher alcohol and glycerol are mixed and dissolved in the base under heating, and the resultant solution is mixed with an aqueous solution of potassium carbonate to obtain aliphatic potassium carbonate salt. 1pt. of the aliphatic potassium carbonate salt is mixed with 2pts. of the base. The obtained mixture is kneaded with 7-10% bentonite, then with 5-10% lanolin to obtain the objective pasty remedy for athlete's foot. Salicylic acid acts as a disinfectant, lactic acid mitigates the stimulation of the salicylic acid, lanolin protects the surface of the diseased skin, and bentonite reduces the viscosity and mitigates the irritant action of each component to the skin.
Patients randomized to the supra-umbilical transverse incision arm will undergo a transverse skin incision halfway between the umbilicus and xiphoid process, extending laterally to the semilunar lines. Subcutaneous tissue will be bluntly dissected until anterior rectus sheath is exposed. A transverse incision will be made through the rectus sheath in line with the skin incision, avoiding injury to the superior epigastric vessels. Rectus muscles will be split manually along midline using blunt dissection. The peritoneum will be incised transversely and the hysterotomy extended laterally with uterine traction to deliver fetus. The visceral peritoneum will not be closed. Rectus muscles will not be re-approximated. Subcutaneous tissue will not be irrigated. Subcutaneous tissue will be closed if over 2cm depth. Skin will be closed with non-absorbable suture subcuticularly.
PURPOSE: To obtain spherical polymer-metal compd. composite particles having a high functionality by dispersing spherical polymer particles as a core into an aq. soln. of a hydrolyzable metal salt uniformly and arranging a uniform covering layer of a metal compd. on the spherical polymer particles. CONSTITUTION: Spherical polymer (such as a styrene polymer) particles as a core are dispersed into an aq. soln. of a hydrolyzable metal salt (such as Y(NO3 )3 ) uniformly. A uniform covering layer of a metal compd. is arranged on the spherical polymer particles as a core, to obtain spherical polymer-metal compd. composite particles having the desired compsn. The particulate diameter is 0.07-30 μm and the ratio of the particulate inner diameter to the outer diameter is 0.40-0.95. The spherical polymer-metal compd. composite particles are heated at 150 deg.C or higher under an inert gas atmosphere to decompose the polymer forming a core, by which the polymer is converted into carbon, to obtain the spherical carbon-metal compd. composite particles. The particulate diameter is 0.05-20 μm and the ratio of the inner diameter to the outer diameter is 0.30-0.93.